BR112023018256A2 - Antagonistas de actrii-alk4 e métodos para tratar insuficiência cardíaca - Google Patents
Antagonistas de actrii-alk4 e métodos para tratar insuficiência cardíacaInfo
- Publication number
- BR112023018256A2 BR112023018256A2 BR112023018256A BR112023018256A BR112023018256A2 BR 112023018256 A2 BR112023018256 A2 BR 112023018256A2 BR 112023018256 A BR112023018256 A BR 112023018256A BR 112023018256 A BR112023018256 A BR 112023018256A BR 112023018256 A2 BR112023018256 A2 BR 112023018256A2
- Authority
- BR
- Brazil
- Prior art keywords
- actrii
- alk4
- heart failure
- methods
- antagonists
- Prior art date
Links
- 206010019280 Heart failures Diseases 0.000 title abstract 5
- 239000005557 antagonist Substances 0.000 title abstract 5
- 230000032683 aging Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1796—Receptors; Cell surface antigens; Cell surface determinants for hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163159059P | 2021-03-10 | 2021-03-10 | |
| PCT/US2022/019557 WO2022192404A1 (en) | 2021-03-10 | 2022-03-09 | Actrii-alk4 antagonists and methods of treating heart failure |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023018256A2 true BR112023018256A2 (pt) | 2023-10-31 |
Family
ID=83228300
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023018256A BR112023018256A2 (pt) | 2021-03-10 | 2022-03-09 | Antagonistas de actrii-alk4 e métodos para tratar insuficiência cardíaca |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240197902A1 (https=) |
| EP (1) | EP4304715A4 (https=) |
| JP (1) | JP2024511315A (https=) |
| KR (1) | KR20230169123A (https=) |
| CN (1) | CN117396224A (https=) |
| AU (1) | AU2022235082A1 (https=) |
| BR (1) | BR112023018256A2 (https=) |
| CA (1) | CA3211515A1 (https=) |
| MX (1) | MX2023010442A (https=) |
| WO (1) | WO2022192404A1 (https=) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA41920B1 (fr) * | 2015-04-06 | 2021-05-31 | Acceleron Pharma Inc | Protéines de fusion de récepteur type i et type ii à bras unique et leurs utilisations |
| MA41919A (fr) * | 2015-04-06 | 2018-02-13 | Acceleron Pharma Inc | Hétéromultimères alk4:actriib et leurs utilisations |
| DK3496739T3 (da) * | 2016-07-15 | 2021-05-10 | Acceleron Pharma Inc | Sammensætninger omfattende actriia-polypeptider til brug i behandlingen af pulmonal hypertension |
| CA3039573A1 (en) * | 2016-10-05 | 2018-04-12 | Acceleron Pharma Inc. | Alk4:actriib heteromultimers and uses thereof |
| GB201620119D0 (en) * | 2016-11-29 | 2017-01-11 | Pharmafox Therapeutics Ag | Compounds |
| JP7669291B2 (ja) * | 2019-05-30 | 2025-04-28 | アクセレロン ファーマ インコーポレーテッド | Ａｃｔｒｉｉ結合性タンパク質及びその使用 |
| US20230174620A1 (en) * | 2020-04-28 | 2023-06-08 | Acceleron Pharma Inc. | Actrii proteins and use in treating post-capillary pulmonary hypertension |
| JP2023534127A (ja) * | 2020-06-17 | 2023-08-08 | アクセルロン ファーマ インコーポレイテッド | ＡｃｔＲＩＩ－ＡＬＫ４アンタゴニストおよび心不全を処置する方法 |
-
2022
- 2022-03-09 JP JP2023554808A patent/JP2024511315A/ja active Pending
- 2022-03-09 AU AU2022235082A patent/AU2022235082A1/en active Pending
- 2022-03-09 BR BR112023018256A patent/BR112023018256A2/pt unknown
- 2022-03-09 KR KR1020237034038A patent/KR20230169123A/ko active Pending
- 2022-03-09 CN CN202280034554.6A patent/CN117396224A/zh active Pending
- 2022-03-09 EP EP22767900.8A patent/EP4304715A4/en active Pending
- 2022-03-09 CA CA3211515A patent/CA3211515A1/en active Pending
- 2022-03-09 MX MX2023010442A patent/MX2023010442A/es unknown
- 2022-03-09 US US18/549,461 patent/US20240197902A1/en active Pending
- 2022-03-09 WO PCT/US2022/019557 patent/WO2022192404A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| US20240197902A1 (en) | 2024-06-20 |
| WO2022192404A1 (en) | 2022-09-15 |
| CA3211515A1 (en) | 2022-09-15 |
| EP4304715A4 (en) | 2025-01-01 |
| JP2024511315A (ja) | 2024-03-13 |
| CN117396224A (zh) | 2024-01-12 |
| EP4304715A1 (en) | 2024-01-17 |
| KR20230169123A (ko) | 2023-12-15 |
| AU2022235082A1 (en) | 2023-09-21 |
| MX2023010442A (es) | 2023-11-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022025473A2 (pt) | Antagonistas de actrii-alk4 e métodos de tratamento de insuficiência cardíaca | |
| CY1124277T1 (el) | Συνθεσεις που περιλαμβανουν πολυπεπτιδα actriia για χρηση στη θεραπεια πνευμονικης υπερτασης | |
| BR112018077300A2 (pt) | uso de antagonistas de neurocinina-1 para tratar diversas condições pruríticas | |
| EA201792545A1 (ru) | Способы и наборы для лечения депрессии | |
| BR112018074924A2 (pt) | métodos e sistemas para gerar automaticamente uma ação corretiva em uma instalação industrial | |
| MX2022000128A (es) | Desarrollo de clasificadores para estratificar pacientes. | |
| MY192409A (en) | Business processing method and apparatus | |
| BR112017002283A2 (pt) | método e aparelho para gerar automaticamente um dicionário de eventos em uma rede de internet das coisas (iot) | |
| SG11201907518UA (en) | Risk management and control method and device | |
| BR112016030026A2 (pt) | operação duplex total em uma rede de comunicação sem fio | |
| NO20093459L (no) | Fremgangsmater og systemer for selvforbedring av resonneringsverktoy | |
| BR112018070091B1 (pt) | sistemas e métodos para fornecer verificação de identidade pessoal multifator baseada em cadeia de blocos. | |
| BR112015015259A2 (pt) | método, aparelhos e dispositivo eletrônico para gerenciamento de conexão | |
| BR112018002466A2 (pt) | proteção de conteúdo aplicado em hardware para unidades de processamento gráfico | |
| BR112017009053A2 (pt) | dispositivo para inibição da atividade neural de um nervo do seio carotídeo ou corpo carotídeo, método para tratamento de uma condição, forma de onda elétrica neuromodulatória, e, uso de um dispositivo de neuromodulação para o tratamento de uma condição. | |
| BR112023018283A2 (pt) | Antagonistas de actrii-alk4 e métodos para tratar insuficiência cardíaca | |
| BR112018010160A8 (pt) | inibidor da c1 esterase humana recombinante e usos do mesmo | |
| BR112017016114A2 (pt) | método para tratar adaptação de taxa de codec em uma rede de comunicação, dispositivo sem fio, nó de rede, programa de computador, e, produto de programa de computador. | |
| Shan et al. | A comment on sample size calculation for analysis of covariance in parallel arm studies | |
| EA202091268A1 (ru) | Способ определения по меньшей мере одной пороговой величины по меньшей мере одного рабочего параметра ядерного реактора и соответствующие компьютерная программа и электронная система | |
| BR112023018256A2 (pt) | Antagonistas de actrii-alk4 e métodos para tratar insuficiência cardíaca | |
| MX2016008798A (es) | Viscosificante para el tratamiento de una formacion subterranea. | |
| GB2535116A (en) | Temperature-triggered viscosifier for treatment of a subterranean formation | |
| BR112022005166A2 (pt) | Composição de aplicação à pele | |
| PH12021550121A1 (en) | Methods of treating hfpef employing dapagliflozin and compositions comprising the same |